Efficacy and safety of apatinib plus EGFR-TKI as a first-line treatment for advanced non-squamous non-small cell lung cancer with activating EGFR mutations

CHEN Runzhi; LEI Hao; XU Huiting; XUE Chang; YU Ding; WU Huijing

doi:10.3969/j.issn.1009-0460.2021.12.013

Home>Articles>Efficacy and safety of apatinib plus EGFR-TKI as a first-line treatment for advanced non-squamous non-small cell lung cancer with activating EGFR mutations

DOI: 10.3969/j.issn.1009-0460.2021.12.013

Efficacy and safety of apatinib plus EGFR-TKI as a first-line treatment for advanced non-squamous non-small cell lung cancer with activating EGFR mutations

CHEN Runzhi

LEI Hao

XU Huiting

XUE Chang

YU Ding

WU Huijing

Machine-generated Keywords：

Publication Date：2021-12-28

Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)

Pages：5( 1131-1135 )

Chinese Clinical Oncology

ISTICPKU

ISSN：1009-0460

Year, Vol.(Issue)：2021,26(12)